Evidence map›Paper›PMID 40683139›Full record

ReviewVaccine2025

A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women.

Flor M Munoz, Beate Kampmann, Andy Stergachis, Manu Chaudhary, Clare L Cutland, Asma Khalil, Angela Gentile, Christine E Jones, Helen Marshall, Esperanca Sevene and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Flor M MunozDepartments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. Electronic address: florm@bcm.edu.
Beate KampmannCharité - Universitätsmedizin Berlin, Berlin, Germany and LSTMH, London, UK. Electronic address: Beate.Kampmann@lshtm.ac.uk.
Andy StergachisSchool of Pharmacy, University of Washington, Seattle, WA, and School of Public Health, University of Washington, Seattle, WA, USA. Electronic address: stergach@uw.edu.
Manu ChaudharyDepartment of Infectious Diseases, Rainbow Children's Hospital, Bangalore, India.
Clare L CutlandWits African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: Clare.Cutland@wits.ac.za.
Asma KhalilFetal Medicine Unit, St George's University of London, London, UK. Electronic address: akhalil@sgul.ac.uk.
Angela GentileEpidemiology Department, Ricardo Gutierrez Children Hospital, University of Buenos Aires, Argentina.
Christine E JonesFaculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, and NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS, Southampton, UK. Electronic address: C.E.Jones@soton.ac.uk.
Helen MarshallWomen's and Children's Health Network, and The University of Adelaide, Adelaide, SA, Australia. Electronic address: helen.marshall@adelaide.edu.au.
Esperanca SeveneDepartment of Physiological Science, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
Delese Mimi DarkoNigeria Centre for Disease Control and Prevention, Abuja, Nigeria.
Geeta SwamyDepartment of Obstetrics & Gynecology, Duke University, Durham, NC, USA. Electronic address: geeta.swamy@duke.edu.
Terri B HydeCenters for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: thyde@cdc.gov.
Gerald VossCoalition for Epidemic Preparedness Innovations (CEPI) London, UK. Electronic address: gerald.voss@cepi.net.
Ajoke Sobanjo-Ter MuelenDepartment of Global Health, University of Washington, Seattle, Washington, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Vaccination during pregnancy provides effective protection against pathogens that increase the risk of maternal and infant morbidity and mortality for mothers and their infants. The SARS-CoV-2 pandemic demonstrated the need for the inclusion of pregnant and breast-feeding women in research and development of vaccines for emerging pathogens, such as Ebola, Zika, Lassa fever, Chikungunya, and influenza virus of pandemic potential. The COVID-19 Vaccines Global Access (COVAX) Maternal Immunization Working Group (MIWG), in collaboration with the Coalition for Epidemic Preparedness Innovation and the Safety Platform for Emergency Vaccines (CEPI-SPEAC) developed a standardized template with key considerations to guide the assessment of vaccines against emerging pathogens in pregnant and breast-feeding women. The aim of this tool is to enable key stakeholders to perform an early structured assessment of the overall potential benefit and risk for maternal immunization against an emerging pathogen. It can also be used to support risk management and pharmacovigilance planning, communication strategies, policy development, and acceptance of vaccination during pregnancy in future pandemics.

Indexed as

Breast FeedingCommunicable Diseases, EmergingCOVID-19COVID-19 VaccinesPregnancy Complications, InfectiousVaccinesFemaleHumansPregnancySARS-CoV-2VaccinationCOVID-19 VaccinesVaccinesBenefit-riskEmerging pathogensMaternal vaccinationPandemicSafety surveillanceTemplateVaccines

Identifiers

PMID40683139
PMCPMC12797864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.